Safer dialysis for bleeding patients? citrate vs. heparin tested
NCT ID NCT03562754
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested two ways to prevent blood clots during dialysis in 60 patients at high risk of bleeding. One method used a special blood thinner called citrate, the other used a low dose of standard heparin. The goal was to see which approach allowed dialysis to run longer and more safely. Results could help doctors choose the best option for fragile patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
citrate (regional citrate anticoagulation) versus low-dose heparin
What this could lead to
If successful, this could show that citrate is a safer blood-thinner option during dialysis for patients at risk of bleeding.
What could go wrong
This is a small, single-center trial with only 60 participants, so results may not apply broadly. Both methods have risks like clotting or metabolic issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Nimes
Nîmes, 30029, France